Renaissance Capital logo

Brainsway Priced, Nasdaq: BWAY

Sells medical devices that use magnetic stimulation to treat depression and OCD.

Industry: Health Care

Latest Trade: $10.25 0.00 (0.0%)

First Day Return: +0.8%

Return from IPO: -6.8%

Industry: Health Care

We are a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using our proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which we have received marketing authorization from the FDA. Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. Our technology can either increase brain activity in neuronal networks which are hypoactive, or alternatively decrease brain activity in neuronal networks which are hyperactive. Our proprietary electromagnetic coils, which we refer to as H-Coils, are designed to safely stimulate deep and broad brain regions, which we believe provides an advantage over other available TMS products, which we refer to collectively as Focal TMS, that generally use a "figure 8" design. We believe that our Deep TMS technology has the potential to be safe and effective for the treatment of a wide range of psychiatric, neurological and addiction disorders beyond MDD and OCD.
more less
IPO News for Brainsway
more
IPO Data
IPO File Date 01/14/2019
Offer Price $11.00
Price Range $11.00 - $11.00
Offer Shares (mm) 2.5
Deal Size ($mm) $28
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/16/2019
Offer Price $11.00
Price Range $11.00 - $11.00
Offer Shares (mm) 2.5
Deal Size ($mm) $28
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Jerusalem, Israel
Founded 2003
Employees 96
Website www.brainsway.com